Overview

• Denmark allergy treatment firm's Q4 revenue rose 17% to DKK 1,733 mln

• Q4 EBIT increased 88% to DKK 387 mln, reflecting planned growth investments

• Company proposes DKK 355 mln dividend for 2025, about 30% of net profit

Outlook

• ALK expects 2026 revenue growth of 11-15% in local currencies

• Company projects 2026 EBIT margin around 25%

• Growth driven by increased patient treatment with AIT and anaphylaxis products

Result Drivers

• TABLET SALES - Tablet sales increased by 15% to DKK 910 mln, driven by expanding patient and prescriber bases in Europe and North America

• ANAPHYLAXIS PRODUCTS - Sales of anaphylaxis and other products rose 50% to DKK 216 mln, driven by Jext and neffy

• GROWTH INVESTMENTS - Operating profit increased 88% to DKK 387 mln, reflecting planned growth investments

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for ALK-Abello A/S is DKK257.50, about 17% above its February 19 closing price of DKK220.00

• The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 34 three months ago

Press Release: ID:nGNE61ybwJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)